Novartis: Decentralized trials could expand enterprise around the world

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/RomoloTavani)
(Image: Getty/RomoloTavani)
Novartis hopes to eventually recruit ‘a significant portion’ of patients into a decentralized clinical trial model that has the potential to increase the company’s reach globally, says exec.

Last week Novartis and Science 37 announced​ an expanded alliance through which the companies will launch up to 10 “decentralized” clinical trials across the US.

Decentralized trials shift some or all aspects of a clinical trial from a central site, such as a hospital, to the participant’s home or physician’s office.

“By bringing the trial to the patient, Novartis aims to decrease the burden of clinical trial participation on patients and trial centers,”​ Jake LaPorte, global head of digital development at Novartis told Outsourcing-Pharma.com.

The more flexible approach also could benefit underrepresented populations.

LaPorte said: “This approach also has the potential to increase the reach of our leading drug development and clinical trials enterprise into under-represented and underserved populations around the world, improving the caliber and quantity of data available to aid in drug discovery and development.”

Currently, Novartis is in the process of selecting specific indication and trials where it will deploy the decentralized approach, which leverages Science 37’s technology to enable patient participation using mobile devices and telemedicine services.

LaPorte said the characteristics of the target patient population, including size, will be defined after these decisions have been made.

The studies will use both decentralized and traditional models, “with the aspiration of attaining increasing degrees of decentralization towards a mostly ‘site-less’ model overtime,”​ he added.

Our aspiration, overtime, is to recruit a significant portion of patients into this decentralized model when deployed on a clinical trial.”

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars